AU2455199A - Compositions and methods for regulated secretion from neuroendocrine cell lines - Google Patents

Compositions and methods for regulated secretion from neuroendocrine cell lines

Info

Publication number
AU2455199A
AU2455199A AU24551/99A AU2455199A AU2455199A AU 2455199 A AU2455199 A AU 2455199A AU 24551/99 A AU24551/99 A AU 24551/99A AU 2455199 A AU2455199 A AU 2455199A AU 2455199 A AU2455199 A AU 2455199A
Authority
AU
Australia
Prior art keywords
compositions
methods
cell lines
neuroendocrine cell
regulated secretion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24551/99A
Inventor
Samuel A. Clark
Anice E. Thigpen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betagene Inc
Original Assignee
Betagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betagene Inc filed Critical Betagene Inc
Publication of AU2455199A publication Critical patent/AU2455199A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate
AU24551/99A 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines Abandoned AU2455199A (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US7119398P 1998-01-12 1998-01-12
US7120998P 1998-01-12 1998-01-12
US7255698P 1998-01-12 1998-01-12
US60071193 1998-01-12
US60071209 1998-01-12
US60072556 1998-01-12
US8784898P 1998-06-03 1998-06-03
US8782198P 1998-06-03 1998-06-03
US60087848 1998-06-03
US60087821 1998-06-03
PCT/US1999/000631 WO1999035255A2 (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines

Publications (1)

Publication Number Publication Date
AU2455199A true AU2455199A (en) 1999-07-26

Family

ID=27535873

Family Applications (3)

Application Number Title Priority Date Filing Date
AU21131/99A Abandoned AU2113199A (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
AU21121/99A Abandoned AU2112199A (en) 1998-01-12 1999-01-11 Recombinant cell lines for drug screening
AU24551/99A Abandoned AU2455199A (en) 1998-01-12 1999-01-11 Compositions and methods for regulated secretion from neuroendocrine cell lines

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AU21131/99A Abandoned AU2113199A (en) 1998-01-12 1999-01-11 Media for neuroendocrine cells
AU21121/99A Abandoned AU2112199A (en) 1998-01-12 1999-01-11 Recombinant cell lines for drug screening

Country Status (4)

Country Link
EP (2) EP1045898A2 (en)
AU (3) AU2113199A (en)
CA (2) CA2318379A1 (en)
WO (3) WO1999035242A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2281764C2 (en) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Medicinal agents for treatment of complications associated with diabetes mellitus and neuropathy and their using
US7501231B2 (en) 2001-03-23 2009-03-10 University Of Ottawa Methods and compositions for cryopreservation of dissociated primary animal cells
US7166463B2 (en) 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
WO2006133506A1 (en) 2005-06-17 2006-12-21 Vital Health Sciences Pty Ltd A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
ATE448247T1 (en) 2005-09-22 2009-11-15 Biocompatibles Uk Ltd FUSION POLYPEPTIDES FROM GLP-1 (GLUCAGON-LIKE PEPTIDE-1) WITH INCREASED PEPTIDE RESISTANCE
CN101360820A (en) 2006-01-04 2009-02-04 巴克斯特国际公司 Oligopeptide-free cell culture media
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
EP2495307B9 (en) 2006-07-13 2018-05-02 Wyeth LLC Production of coagulation factor IX with improved glycosylation pattern
JP2010525818A (en) 2007-05-01 2010-07-29 ヴィトロライフ スウェーデン アクチボラゲット Culture medium for developing cells with increased lipoic acid concentration
RU2010114039A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) USE OF OCTREOTIDE AS A THERAPEUTIC
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
EP3431588A1 (en) * 2009-08-11 2019-01-23 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
AU2011213484B2 (en) * 2010-02-05 2015-07-09 Phosphagenics Limited Carrier composition
EP2531047A4 (en) 2010-02-05 2014-03-19 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
CN102821791B (en) 2010-03-30 2015-06-17 磷肌酸有限公司 Transdermal delivery patch
EP2678415B1 (en) * 2011-02-22 2019-06-19 Promethera Biosciences SA Fill system for providing uniform concentrations and volumes and methods thereof
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US8945876B2 (en) 2011-11-23 2015-02-03 University Of Hawaii Auto-processing domains for polypeptide expression
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
WO2015066631A2 (en) * 2013-11-01 2015-05-07 University Of Notre Dame Du Lac Cell culture medium and bioprocess optimization
ES2716674T3 (en) 2013-11-22 2019-06-14 Centre Nat Rech Scient Frozen cell ready for testing and method to minimize variability in the performance of the same
US10918110B2 (en) 2015-07-08 2021-02-16 Corning Incorporated Antimicrobial phase-separating glass and glass ceramic articles and laminates
TW202330904A (en) * 2015-08-04 2023-08-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
CN108601732A (en) 2015-12-09 2018-09-28 磷肌酸有限公司 pharmaceutical preparation
KR102647670B1 (en) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 method
KR102569522B1 (en) * 2017-11-24 2023-08-24 주식회사 차바이오랩 Composition for cryopreservation of cell and method for cryopreservation of cell using the same
US20230091910A1 (en) * 2019-04-02 2023-03-23 Centagen, Inc. Engineered System of Stem Cell Rejuvenation to Treat Aging and Disease
CN114868736B (en) * 2022-03-08 2022-12-09 四川中科奥格生物科技有限公司 Islet cell stabilizing solution and preparation method and application thereof
CN114561337B (en) * 2022-03-09 2023-10-03 广州源井生物科技有限公司 Monoclonal enhancement culture medium and method for improving clone formation rate of HepG2 cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180662A (en) * 1988-01-05 1993-01-19 The United States Of America As Represented By The Department Of Health And Human Services Cytotoxic T lymphocyte activation assay
US5427940A (en) * 1991-06-03 1995-06-27 Board Of Regents, The University Of Texas System Engineered cells producing insulin in response to glucose
CA2051092C (en) * 1990-09-12 2002-07-23 Stephen A. Livesey Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
EP0550760A1 (en) * 1991-07-18 1993-07-14 Fuji Yakuhin Kogyo Kabushiki Kaisha Serum-free tissue culture medium containing tissue inhibitor of metalloproteinase and method for cell growth
GB9125052D0 (en) * 1991-11-26 1992-01-22 Isis Innovation Culture of bone cells
FR2726005B1 (en) * 1994-10-10 1997-01-03 Adim IMMORTALIZED LINES OF CEREBRAL ENDOTHELIAL CELLS AND THEIR APPLICATIONS FOR THE TREATMENT OF DIFFERENT NEUROLOGICAL OR PSYCHIATRIC PRIMARY AND SECONDARY DISORDERS OR DISEASES
AU718254B2 (en) * 1996-01-19 2000-04-13 Betagene, Inc. Recombinant expression of proteins from secretory cell lines

Also Published As

Publication number Publication date
AU2112199A (en) 1999-07-26
WO1999035495A2 (en) 1999-07-15
WO1999035255A9 (en) 2001-05-31
EP1045898A2 (en) 2000-10-25
WO1999035255A8 (en) 1999-09-10
WO1999035242A1 (en) 1999-07-15
WO1999035255A3 (en) 1999-10-28
EP1047938A2 (en) 2000-11-02
CA2318379A1 (en) 1999-07-15
WO1999035242A9 (en) 1999-09-30
WO1999035255A2 (en) 1999-07-15
AU2113199A (en) 1999-07-26
WO1999035495A3 (en) 1999-11-25
CA2318376A1 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
AU2455199A (en) Compositions and methods for regulated secretion from neuroendocrine cell lines
AU3116800A (en) Compositions and methods for altering cell migration
AU3046299A (en) Method and compositions for water control
AU3901100A (en) Method and composition for waterproofing
AU1610800A (en) Thick-appearing shingle and method and apparatus for making same
GB2348808B (en) Methods and compositions for desensitisation
AU1831597A (en) Methods and compositions for inhibiting hexokinase
AUPP156698A0 (en) New method for hydrogen passivation
AUPO976797A0 (en) Method and composition (III)
AU2349399A (en) R-lansoprazole compositions and methods
AU2030000A (en) Methods and compositions for identifying receptor effectors
AU3069299A (en) Method and apparatus for mitigating junction flows
AU1278100A (en) 2-acylamino-2-deoxy-glucono-1,5-lactones, method for obtaining same, compositions comprising them and uses
AU2243797A (en) Methods and compositions for inhibiting hexokinase
AU4577999A (en) Methods and compositions for inhibiting corrosion
AU5781800A (en) Methods and compositions for assaying analytes
AUPO976597A0 (en) Method and composition (I)
AU1029501A (en) Cleaning-in-place composition and method for using the same
AU7685798A (en) Compositions and methods for preventing adhesion
AU2111399A (en) Wear reducing compositions and methods for their use
AU2664797A (en) Wnt receptor compositions and methods
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU3243199A (en) Methods for assaying type iii secretion inhibitors
AU3020899A (en) Compositions and methods for protein secretion
AU2970299A (en) Compositions and methods for polynucleotide delivery

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase